Franz-Markus Leweke

Franz-Markus Leweke (born July 14, 1965 in Opladen ) is a German psychiatrist and psychotherapist . He is Professor of Psychiatry and Psychotherapy at the Central Institute for Mental Health in Mannheim .

Life

Leweke studied medicine at the University of Cologne and the University of New South Wales in Sydney . After his neurophysiological training and doctorate at the Institute for Neurophysiology of the University of Cologne with Uwe Heinemann, he began his neurological training at the Alfried Krupp Hospital in Essen with Johannes Noth and Peter Berlit and then moved to the Department of Clinical Psychiatry and Psychotherapy at the Hannover Medical School , where he worked with Hinderk Meiners Emrich . There he began his research on the role of cannabinoids and the endocannabinoid system in psychiatric diseases. After completing his psychiatric specialist training , he moved to Bonn to join Christian E. Elger's clinic for epileptology at the university and completed his neurological specialist training. From there, he moved to the Department of General Psychiatry III - Dependency Diseases of the Rheinische Kliniken in Düsseldorf as a senior consultant . After a research stay at The Neurosciences Institute in San Diego , where he worked with Daniele Piomelli , he moved to the Clinic for Psychiatry and Psychotherapy at the University of Cologne as senior physician and later senior physician and head of the research group Experimental and Clinical Neuropsychopharmacology at the Clinic for Psychiatry and Psychotherapy at the University of Cologne, where he was ten Years dedicated to the scientific focus of his work, the research of schizophrenia and affective disorders using clinical, neurochemical and psychopharmacological methods as well as the role of the endocannabinoid system in this context and completed his habilitation in 2004. In 2009 he was appointed professor for psychiatry and psychotherapy at the Central Institute for Mental Health and the Medical Faculty Mannheim at Heidelberg University.

Scientific contribution

With the cannabinoid hypothesis of schizophrenia (together with Hinderk Meiners Emrich and Udo Schneider) and his studies on the role of the endocannabinoid system in schizophrenia, Leweke has made a significant contribution to the therapeutic use of the system (e.g. through cannabidiol ) that is currently being developed. In addition, he was intensively involved in the identification of the first neurochemical biomarker sets for mental illnesses (together with Sabine Bahn).

He was the founding editor of the journal Neuropsychiatry (2012 to 2015) and is co-editor of Cannabis and Cannabinoid Research .

honors and awards

DGPPN Prize for Psychopharmacology 2015
PhD award of the Society for Epilepsy Research 1993 (best German-language dissertation in the field of epileptology)

Web links

Curriculum vitae on the website of the Translational Research Group in Psychiatry at the Central Institute for Mental Health

Individual evidence

Jump up ↑ Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system . Pharmacol Biochem Behav. 1997; 56: 803-7.
^ Leweke FM. Anandamide dysfunction in prodromal and established psychosis . Curr Pharm Des. 2012; 18 (32): 5188-93.
↑ Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia . Transl Psychiatry. 2012; 2: e94.
↑ Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia . PLoS Med. 2006; 3 (8): e327.
↑ Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis . PLoS Med. 2006; 3 (11): e428.
↑ Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. Identification of a biological signature for schizophrenia in serum . Mol Psychiatry. 2012; 17 (5): 494-502.

personal data
SURNAME	Leweke, Franz-Markus
ALTERNATIVE NAMES	Leweke, F. Markus
BRIEF DESCRIPTION	German psychiatrist
DATE OF BIRTH	July 14, 1965
PLACE OF BIRTH	Opladen

[1] Jump up ↑ Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system . Pharmacol Biochem Behav. 1997; 56: 803-7.

[2] Leweke FM. Anandamide dysfunction in prodromal and established psychosis . Curr Pharm Des. 2012; 18 (32): 5188-93.

[3] Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia . Transl Psychiatry. 2012; 2: e94.

[4] Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia . PLoS Med. 2006; 3 (8): e327.

[5] Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis . PLoS Med. 2006; 3 (11): e428.

[6] Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. Identification of a biological signature for schizophrenia in serum . Mol Psychiatry. 2012; 17 (5): 494-502.